• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

HMGCR Gene Record

  • Summary
  • Interactions
  • Claims
  • HMGCR 3156 Druggable Genome

    Alternate Names:

    3156
    3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE
    HMGCR
    LDLCQ3
    142910
    5006
    ENSG00000113161
    OTTHUMG00000102069
    3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE (EC 1.1.1.34) (HMG-COA REDUCTASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P04035]
    HMG-CoA reductase
    3-hydroxy-3-methylglutaryl-coenzyme A reductase
    P04035
    HMDH_HUMAN
    639
    hydroxymethylglutaryl-CoA reductase
    BE0000574
    PA189
    T53585
    NM_000859|NM_001130996
    NP_000850|NP_001124468

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level
    Interpro Short Name HMG_CoA_Rdtase
    Interpro Type Family
    Interpro Name Hydroxymethylglutaryl-CoA reductase, class I/II
    Interpro Acc IPR002202
    Uniprot Status Swiss-Prot
    Target Class Enzymes
    Target Subclass EC:1.1.1.34
    Transmembrane Helix Count 8
    Target Subclass 1.1
    Target Main Class Enzymes
    Gene Biotype PROTEIN_CODING
    GuideToPharmacology Gene Category Name Lanosterol biosynthesis pathway
    GuideToPharmacology Gene Category ID 104
    (10 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    ENZYME

    Publications:

    Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
    Baxter et al., Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight., Trends Endocrinol. Metab.
    Maejima et al., 2004, Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell., Biochem. Biophys. Res. Commun.
    Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
    Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
    Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
    Thompson JF et al., 2009, Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort., Circ Cardiovasc Genet
    Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
    Jafari et al., 2003, Efficacy of alternate-day dosing versus daily dosing of atorvastatin., J. Cardiovasc. Pharmacol. Ther.
    Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
    Cuevas A et al., 2016, HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals., Basic Clin Pharmacol Toxicol
    Davidson, 2002, Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia., Expert Opin Investig Drugs
    Bösel et al., 2005, Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones., J. Neurochem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Cenedella et al., 2003, Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats., J. Lipid Res.
    Pappu et al., 2003, Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia., J. Lab. Clin. Med.
    Liu et al., 2003, Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection., J Pharm Biomed Anal
    Stoebner et al., 2003, [Simvastatin-induced lichen planus pemphigoides]., Ann Dermatol Venereol
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Kocarek et al., 2002, Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes., Drug Metab. Dispos.
    Carbonell et al., 2005, Binding thermodynamics of statins to HMG-CoA reductase., Biochemistry
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Podar et al., 2009, Emerging therapies for multiple myeloma., Expert Opin Emerg Drugs
    Farina et al., 2002, Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells., Clin. Exp. Metastasis
    Abe et al., 2002, Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum., Mol. Genet. Genomics
    Baranova et al., 2002, [Concentration on Diapak C 16 capsules of lovastatin, mevinolinic acid and other inhibitors of biosynthesis of sterins produced by Penicillium citrinum 89]., Antibiot. Khimioter.
    Dimitroulakos et al., Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas., Neoplasia
    Miyazaki et al., 2002, Effects of pravastatin sodium on mevalonate metabolism in common marmosets., J. Biochem.
    Buxbaum et al., 2001, Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide., J. Alzheimers Dis.
    Zhou X et al., 2014, Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase., Bioorg Med Chem
    Chapman et al., 2003, New dimension of statin action on ApoB atherogenicity., Clin Cardiol
    Holdgate et al., 2003, Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin., Biochem. Soc. Trans.
    Davidson, 2002, Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia., Expert Opin Investig Drugs
    Olsson et al., 2002, Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor., Cardiovasc Drug Rev
    McTaggart et al., 2001, Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor., Am. J. Cardiol.
    Hanefeld, Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor., Int. J. Clin. Pract.
    Ye YC et al., 2015, Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients., Chin Med J (Engl)
    Ray SK et al., 2000, Atorvastatin: in the management of hyperlipidaemia., J Postgrad Med
    Morgan et al., 2012, Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects., J. Cardiovasc. Pharmacol.
    Hoy SM, 2017, Pitavastatin: A Review in Hypercholesterolemia., Am J Cardiovasc Drugs
    Blumenthal, 2000, Statins: effective antiatherosclerotic therapy., Am. Heart J.
    Shiomi et al., 1999, Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits., Br. J. Pharmacol.
    Ganné et al., 2000, Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis., Thromb. Haemost.
    Wong et al., 2001, Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin., Clin. Cancer Res.
    Denoyelle et al., 2001, Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study., Carcinogenesis
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Li et al., 2003, 3-hydroxy-3-methylglutaryl-coenzyme A reductase in the lobster mandibular organ: regulation by the eyestalk., Gen. Comp. Endocrinol.
    Hedl et al., 2004, Inhibition of the class II HMG-CoA reductase of Pseudomonas mevalonii., Protein Sci.
    Huber et al., 2005, Improved posthypoxic recovery in vitro on treatment with drugs used for secondary stroke prevention., Neuropharmacology
    Ibeas Bih C et al., 2015, Molecular Targets of Cannabidiol in Neurological Disorders., Neurotherapeutics
  • MEGLUTOL   HMGCR

    Interaction Score: 6.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423


    Sources:
    DrugBank

  • MEVASTATIN   HMGCR

    Interaction Score: 4.56

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Competitive
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    12518039 12677170 12852453 12671581 10592235 11752352 12433810


    Sources:
    DrugBank GuideToPharmacology

  • CERIVASTATIN   HMGCR

    Interaction Score: 4.56

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction Inhibition of HMG-CoA reductase
    Specific Action of the Ligand Competitive
    Endogenous Drug? False

    PMIDs:
    10740137 10193776 11057870 11752352 11448925 11470741


    Sources:
    TTD DrugBank GuideToPharmacology

  • CRILVASTATIN   HMGCR

    Interaction Score: 2.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PRAVASTATIN SODIUM   HMGCR

    Interaction Score: 2.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction HMG-CoA reductase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TOCOTRIENOL   HMGCR

    Interaction Score: 2.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PITAVASTATIN   HMGCR

    Interaction Score: 2.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name pitavastatin , NK-104,Livalo

    PMIDs:
    22472908 28130659


    Sources:
    TEND TdgClinicalTrial DrugBank

  • FLUVASTATIN SODIUM   HMGCR

    Interaction Score: 2.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction HMG-CoA reductase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ROSUVASTATIN CALCIUM   HMGCR

    Interaction Score: 2.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction HMG-CoA reductase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ROSUVASTATIN   HMGCR

    Interaction Score: 1.88

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Competitive
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    12539816 12773150 11772327 12481202 11752352 11256847 16128575 11501230


    Sources:
    TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology

  • FLUVASTATIN   HMGCR

    Interaction Score: 1.38

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name fluvastatin sodium,Lescol and Lescol XL
    Details of the Assay for Interaction Inhibition of HMG-CoA reductase

    PMIDs:
    17563401 18815589 18332269 16103896 18261733 15199031 10592235 11752352 19249983


    Sources:
    TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology

  • LOVASTATIN   HMGCR

    Interaction Score: 1.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name lovastatin,Mevacor, Altocor, Altoprev
    Novel drug target Established target
    Mechanism of Interaction HMG-CoA reductase inhibitor

    PMIDs:
    17563401 18815589 18332269 16103896 12405293 12172803 12369143 18261733 15199031 12082550 12204108 11752352 12214063 24726306 19249983


    Sources:
    ClearityFoundationClinicalTrial TEND DTC PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

  • CERIVASTATIN SODIUM   HMGCR

    Interaction Score: 1.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction HMG-CoA reductase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LAPAQUISTAT ACETATE   HMGCR

    Interaction Score: 1.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DrugBank

  • TERIFLUNOMIDE   HMGCR

    Interaction Score: 1.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PITAVASTATIN CALCIUM   HMGCR

    Interaction Score: 1.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction HMG-CoA reductase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ATORVASTATIN CALCIUM   HMGCR

    Interaction Score: 1.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction HMG-CoA reductase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PRAVASTATIN   HMGCR

    Interaction Score: 0.85

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CRES pravastatin
    Novel drug target Established target
    Trial Name pravastatin and fenofibrate,PravaFen

    PMIDs:
    17563401 25591572 18815589 18332269 11298482 16103896 18261733 15199031 11752352


    Sources:
    TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology

  • SIMVASTATIN   HMGCR

    Interaction Score: 0.8

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name HL 007, simvastatin + amlodipine
    Novel drug target Established target
    Trial Name MK-0542B, extended release niacin + laropiprant +simvastatin

    PMIDs:
    17563401 18815589 18332269 12518039 16103896 12677170 18261733 15199031 12852453 12671581 11752352 16680159 12433810 16128575


    Sources:
    TEND DTC PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

  • COENZYME_A   HMGCR

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423


    Sources:
    DrugBank

  • ATORVASTATIN   HMGCR

    Interaction Score: 0.63

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction In vitro inhibition of HMG-CoA reductase
    Specific Action of the Ligand Competitive
    Endogenous Drug? False

    PMIDs:
    17563401 15109613 15474503 18815589 18332269 16103896 20031582 18261733 12808485 15199031 26408409 12769127 15748157 11752352


    Sources:
    TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology

  • DITHIOTHREITOL   HMGCR

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423


    Sources:
    DrugBank

  • LAROPIPRANT   HMGCR

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SODIUM BETA-NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE   HMGCR

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423


    Sources:
    DrugBank

  • CANNABIDIOL   HMGCR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    stimulator (activating)

    Interaction Info:

    PMIDs:
    26264914


    Sources:
    DrugBank

  • NABIXIMOLS   HMGCR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    stimulator (activating)

    Interaction Info:

    PMIDs:
    26264914


    Sources:
    DrugBank

  • CHEMBL1161866   HMGCR

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14511985 17139284 17016423 15152097 15755483


    Sources:
    DrugBank

  • ASPIRIN   HMGCR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • Ensembl: ENSG00000113161

    • Version: 101_38

    Alternate Names:
    HMGCR Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000113161

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000113161 Ensembl Gene Id
    HMGCR Display Id
    3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE (EC 1.1.1.34) (HMG-COA REDUCTASE). [SOURCE:UNIPROT/SWISSPROT;ACC:P04035] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TEND: P04035

    • Version: 01-August-2011

    Alternate Names:
    HMDH_HUMAN Uniprot Id
    P04035 Uniprot Accession
    3156 Entrez Gene Id

    Gene Info:
    Transmembrane Helix Count 8
    Target Subclass 1.1
    Target Main Class Enzymes

    Publications:

  • TdgClinicalTrial: P04035

    • Version: January-2014

    Alternate Names:
    HMGCR Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:1.1.1.34

    Publications:

  • HopkinsGroom: P04035

    • Version: 11-September-2012

    Alternate Names:
    HMDH_HUMAN Uniprot Id
    HMGCR Uniprot Gene Name
    P04035 Uniprot Accession

    Gene Info:
    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level
    Interpro Short Name HMG_CoA_Rdtase

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GuideToPharmacology: 3156

    • Version: 29-September-2020

    Alternate Names:
    5006 HUGO Gene ID
    5006 HUGO Gene Symbol
    3-hydroxy-3-methylglutaryl-CoA reductase HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name Lanosterol biosynthesis pathway
    GuideToPharmacology Gene Category ID 104

    Gene Categories:
    ENZYME

    Publications:

  • PharmGKB: HMGCR

    • Version: 18-August-2020

    Alternate Names:
    PA189 PharmGKB ID

    Gene Info:

    Publications:
    Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
    Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
    Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation

  • DrugBank: BE0000574

    • Version: 5.1.7

    Alternate Names:
    HMGCR DrugBank Gene Name
    P04035 UniProt Accession
    3156 Entrez Gene Id

    Gene Info:

    Publications:
    Li et al., 2003, 3-hydroxy-3-methylglutaryl-coenzyme A reductase in the lobster mandibular organ: regulation by the eyestalk., Gen. Comp. Endocrinol.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

  • DTC: HMGCR

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Zhou X et al., 2014, Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase., Bioorg Med Chem

  • HingoraniCasas: ENSG00000113161

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000113161 Gene Symbol
    HMGCR Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: HMGCR

    • Version: chembl_23

    Alternate Names:
    HMGCR GENE_SYMBOL
    3-hydroxy-3-methylglutaryl-coenzyme A reductase UNIPROT
    HMG-CoA reductase UNIPROT

    Gene Info:

    Publications:

  • Pharos: HMGCR

    • Version: 03-September-2020

    Alternate Names:
    3-hydroxy-3-methylglutaryl-coenzyme A reductase Gene Name
    P04035 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • TTD: HMG-CoA reductase

    • Version: 2020.06.01

    Alternate Names:
    HMGCR TTD Gene Abbreviation
    T53585 TTD Target ID

    Gene Info:

    Publications:

  • ClearityFoundationClinicalTrial: HMGCR

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21